Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers with very few available treatments. For many decades, gemcitabine was the only treatment for patients with PDAC. A recent attempt to improve patient survival by combining this chemotherapy with FOLFIRINOX and nab-paclitaxel failed and instead resulted in increased toxicity. Novel therapies are urgently required to improve PDAC patient survival. New treatments in other cancers such as melanoma, non-small-cell lung cancer, and renal cancer have emerged, based on immunotherapy targeting the immune checkpoints cytotoxic T-lymphocyte-associated antigen 4 or programmed death 1 ligand. However, the first clinical trials using such immune checkpoint inhibitors in PDAC have had limited success. Resistance to immunotherapy in PDAC remains unclear but could be due to tissue components (cancer-associated fibroblasts, desmoplasia, hypoxia) and to the imbalance between immunosuppressive and effector immune populations in the tumor microenvironment. In this review, we analyzed the presence of "good and bad immunological cops" in PDAC and discussed the significance of changes in their balance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · cited 3×
“More recently, studies found that using gemcitabine in combination with FOLFIRINOX and nab-paclitaxel was more effective than gemcitabine monotherapy (3).”
BackgroundElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · cited 1×
“Immune-based strategies to treat various cancers during the early stages of development, as well as new immunological approaches to treat advanced disease, are showing significant promise where other approaches have failed (63, 64).”
BackgroundGenomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 1×
“Indeed, several genetic and transcriptomic studies have demonstrated the classification of PDAC into two or more subtypes including basal versus classic or immunogenic versus non-immunogenic (72).”
BackgroundMoffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194
Integrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019
Smoldering and polarized inflammation in the initiation and promotion of malignant disease
Balkwill, F., Charles, K. A., & Mantovani, A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.013 · Cited by 1,769
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Beatty, G. L., & Gladney, W. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1860 · Cited by 1,078 · cited 1×
“A large number of cells or mechanisms participate together to improve the proliferation of tumor cells (4, 5).”
BackgroundNomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889 · cited 1×
“Furthermore, PDAC cells express PD-L1, which binds to PD1 expressed on activated T cells (17).”
Background
Cited by
Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
Sarantis, P., Koustas, E., Papadimitropoulou, A., Papavassiliou, A. G., & Karamouzis, M. V. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i2.173 · Cited by 472
Kurz, E., Hirsch, C. A., Dalton, T., Shadaloey, S. A., Khodadadi-Jamayran, A., Miller, G., Pareek, S., Rajaei, H., Mohindroo, C., Baydogan, S., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.05.006 · Cited by 258
Why is pancreatic cancer so deadly? The pathologist's view
Hruban, R. H., Gaida, M. M., Thompson, E., Hong, S., Noë, M., Brosens, L. A., Jongepier, M., Offerhaus, G. J. A., & Wood, L. D. (2019) · The Journal of Pathology · doi:10.1002/path.5260 · Cited by 115
“The immune infiltrate, or tumor immune microenvironment (TiME), is increasingly recognized in multiple tumor types as a potential driver of patient outcome [109,110].”
BackgroundBarrett, A. M., Britton, Z. T., Carrasco, R. A., Breen, S., Broggi, M. A. S., Hatke, A. L., Clark, B., Yang, C., Phipps, S., Ortiz, L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1853 · Cited by 43
Metadata
- Authors
- Foucher, E. D., Ghigo, C., Chouaib, S., Galon, J., Iovanna, J., & Olive, D.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-05-14
- Volume
- 9
- Pages
- 1044-1044
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2799673576
- Cited by
- 138
- References
- 15
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. https://app.cochat.ai/papers/10.3389/fimmu.2018.01044
- The paper
- Foucher, E. D., Ghigo, C., Chouaib, S., Galon, J., Iovanna, J., & Olive, D. (2018). Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2018.01044
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.